Physiological_JJ
concentration_NN
of_IN
estradiol_NN
inhibits_VBZ
polymorphonuclear_JJ
leukocyte_NN
chemotaxis_NN
via_IN
a_DT
receptor_NN
mediated_JJ
system_NN
._.

Estrogen_NN
exhibits_VBZ
a_DT
variety_NN
of_IN
actions_NNS
,_,
including_VBG
immuno-modulatory_JJ
effects_NNS
,_,
in_FW
vivo_FW
and_CC
in_FW
vitro_FW
._.

The_DT
mechanism_NN
by_IN
which_WDT
estrogen_NN
exerts_VBZ
its_PRP$
anti-inflammatory_JJ
effect_NN
is_VBZ
not_RB
yet_RB
understood_VBN
._.

We_PRP
investigated_VBD
the_DT
possible_JJ
mechanisms_NNS
of_IN
estradiol_NN
acting_VBG
via_IN
the_DT
polymorphonuclear_JJ
leukocytes_NNS
-LRB-_-LRB-
PMNs_NNS
-RRB-_-RRB-
,_,
which_WDT
are_VBP
important_JJ
in_IN
the_DT
immune_JJ
response_NN
._.

The_DT
agent_NN
,_,
17_CD
beta-estradiol_NN
,_,
but_CC
not_RB
17_CD
alpha-estradiol_NN
,_,
significantly_RB
reduced_VBD
PMNs_NNS
chemotaxis_NN
to_TO
FMLP_NN
in_IN
a_DT
dose-dependent_JJ
manner_NN
-LRB-_-LRB-
control_NN
vs_CC
estrogen_NN
10_CD
-LRB-_-LRB-
-10_CD
-RRB-_-RRB-
-_:
-LRB-_-LRB-
-6_CD
-RRB-_-RRB-
M_NN
,_,
P_NN
&lt;_JJR
0.05_CD
-RRB-_-RRB-
._.

Physiological_JJ
concentrations_NNS
of_IN
estradiol_NN
significantly_RB
reduced_VBD
the_DT
chemotaxis_NN
of_IN
PMNs_NNS
-LRB-_-LRB-
10_CD
-LRB-_-LRB-
-10_CD
-RRB-_-RRB-
mol_NN
-RRB-_-RRB-
._.

Pre-incubation_NN
with_IN
clomiphene_NN
or_CC
tamoxifen_NN
which_WDT
are_VBP
estrogen_NN
receptor_NN
antagonists_NNS
,_,
eliminated_VBD
the_DT
inhibitory_JJ
effect_NN
of_IN
17_CD
beta-estradiol_NN
on_IN
the_DT
chemotaxis_NN
of_IN
PMNs_NNS
,_,
restoring_VBG
it_PRP
to_TO
the_DT
control_NN
level_NN
._.

These_DT
observations_NNS
suggest_VBP
that_IN
17_CD
beta-estradiol_NN
suppressed_VBD
the_DT
chemotaxis_NN
of_IN
PMNs_NNS
by_IN
a_DT
receptor-dependent_JJ
mechanism_NN
._.

In_IN
addition_NN
,_,
the_DT
level_NN
of_IN
estradiol_NN
in_IN
human_JJ
plasma_NN
,_,
which_WDT
PMNs_NNS
were_VBD
drawn_VBN
,_,
showed_VBD
a_DT
close_JJ
,_,
inverse_JJ
correlation_NN
with_IN
the_DT
PMNs_JJ
chemotaxis_NN
to_TO
FMLP_NN
-LRB-_-LRB-
r_NN
=_JJ
-0.821_CD
p_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
._.

Estrogen_NN
may_MD
modify_VB
the_DT
activity_NN
of_IN
neutrophils_NNS
during_IN
the_DT
normal_JJ
menstrual_JJ
cycle_NN
,_,
not_RB
only_RB
during_IN
pregnancy_NN
,_,
and_CC
influence_VB
inflammation_NN
._.

